News Article

Germany-based multinational life science company Bayer is to fully acquire San Francisco based biopharmaceutical firm Perfuse Therapeutics for a total potential value of up to $2.45bn, signalling a robust return to strategic merger and acquisition activity.

The transaction comprises a $300m upfront cash payment, alongside up to $2.15bn in contingent payments linked to specific development, regulatory, and commercial milestones.  The deal is slated to close in the second half of 2026, subject to customary antitrust clearances and approval from Perfuse stockholders

Bayer is actively navigating a comprehensive corporate turnaround to offset revenue pressures from impending patent expirations and biosimilar competition targeting its top selling retinal drug, Eylea. By purchasing Perfuse Therapeutics, Bayer secures a vital asset to defend its lucrative ophthalmology franchise and replenish its mid-stage clinical pipeline. The capital deployment aligns with the company’s broader operational restructure, which targets €2bn in organisational savings by the end of the year to facilitate reinvestment in innovative research. 

The centrepiece of the takeover is PER-001, an investigational, first-in-class small molecule endothelin receptor antagonist.  Delivered every six months via a sustained release bio-erodible intravitreal implant, the therapy diverges from traditional treatments that merely lower intraocular pressure. Instead, PER-001 targets the underlying vascular causes of vision loss by blocking proteins that constrict blood vessels, aiming to improve retinal blood flow and mitigate ischemia.

Currently in Phase II clinical development, PER-001 is being evaluated as a disease-modifying intervention for open angle glaucoma and diabetic retinopathy.   Both conditions represent vast areas of unmet medical need; glaucoma currently affects up to 80 million people globally, while diabetic retinopathy impacts approximately 146 million individuals.